Ivonescimab in China: Lung Cancer Indications, FDA Status and Patient Access
Home > Blog > Travel & Hospital Navigation By MedBridgeNZ · Regulatory information checked 22 November 2026
When a scan shows that a family member’s lung cancer has progressed, it can be hard to know what to do with the new drug names you come across. If ivonescimab is on that list, start with the type of lung cancer on the pathology report and which treatments your family member has already had. Those details will help the oncologist judge whether the drug is relevant.
China has approved ivonescimab for three specific uses in advanced non-small cell lung cancer (NSCLC). As of 22 November 2026, ivonescimab is not FDA-approved in the US. If you’re exploring care in China, you can start with a video consultation before making travel plans. MedBridgeNZ can help arrange one with Jiahui International Cancer Center or GoBroad.
Which lung cancer uses are approved in China?
Ivonescimab, sold in China as 依达方, is given through a vein. It targets two proteins, PD-1 and VEGF-A, involved in the immune response and blood vessel growth. You may also see the names 依沃西单抗, AK112 or SMT112 in reports or research.

Use the table to find the terms to look for in the records you already have. Your oncologist can explain which approved use, if any, fits your situation. For the exact wording of each approved use, see the Chinese prescribing information.
What to look for in your records | Approved use in China |
The cancer progressed after an EGFR-targeted medicine. The label covers locally advanced or metastatic non-squamous NSCLC with an EGFR mutation, when the cancer has progressed after an EGFR tyrosine kinase inhibitor (EGFR-TKI). | Ivonescimab with pemetrexed and carboplatin. |
The PD-L1 report is positive and both EGFR and ALK results are negative. For locally advanced or metastatic NSCLC, the Chinese label requires a PD-L1 tumour proportion score (TPS) of at least 1% on a test approved by China’s drug regulator. | Ivonescimab on its own as first-line treatment. |
The pathology report says squamous NSCLC. This use covers unresectable locally advanced disease or disease that has spread to distant parts of the body. | Ivonescimab with paclitaxel and carboplatin as first-line treatment. |
“First-line” means the initial treatment for the cancer in that setting. The date the last treatment started and the scan that showed progression can be just as useful to bring to your consultation as the biomarker results.
Is ivonescimab FDA-approved in the US?
No. The FDA said it could not approve the application as submitted. It was reviewing ivonescimab plus chemotherapy for people whose EGFR-mutated lung cancer had progressed after targeted treatment. The trial showed a longer time before the cancer worsened or patients died, but it did not establish a statistically significant improvement in how long patients lived. The FDA judged the benefit insufficient to outweigh the added risks for that use. The FDA gave its reasons in its Complete Response Letter dated 13 November 2026.
The study you may have seen in the news compared ivonescimab with pembrolizumab (Keytruda) as the first treatment for a selected group with PD-L1-positive lung cancer. It reported a survival benefit in a planned interim analysis. The Keytruda study update describes that first-line comparison. The trial table below shows how it differs from the study used in the US application.
Can international patients start with a video consultation?
Yes. MedBridgeNZ can help arrange a video consultation with an oncologist at Jiahui International Cancer Center or GoBroad. If you’re helping a family member, tell us what you’d like the doctor to clarify and which reports you already have. You can make an initial enquiry while you’re still gathering records.
Tell us what you have. Start with the diagnosis, your main question and a brief list of the reports you can access. Our coordination team normally reviews initial enquiries within 1–2 business days. That is our review time. The hospital’s video appointment is scheduled separately.
Work out the details with us. We can help organise and translate your records. Before you book a video consultation, we can check the fee, available times and language arrangements with the hospital. If you need an interpreter or a written summary, we can check what’s available.
Speak with the oncologist. The hospital team reviews the records and discusses whether ivonescimab is worth considering, what else it needs to check and whether a visit to China would be useful. The hospital confirms any proposed treatment, availability and next steps after assessing the case.
Keep your current oncology team informed while arranging a second opinion. For a preparation checklist, see our guide to remote cancer second opinions.
Which records should you gather?
A one-page treatment timeline can help the doctor see what happened between scans. Use the dates you know and flag any gaps.
Record | Why it helps |
Pathology report | Gives the cancer diagnosis and its subtype, such as squamous or non-squamous NSCLC. |
Existing EGFR, ALK and PD-L1 reports | Shows the exact biomarker results, including the PD-L1 score if reported. |
Treatment names, dates and reasons for stopping or switching | Shows which treatments were tried and when progression or side effects were reported. |
Recent scan reports and original DICOM image files, if available | Lets the team see what has changed and review the images if needed. |
Current medicines and relevant medical history | Helps the doctor identify issues to consider during the assessment. |
Start with your pathology report. If the hospital asks for slides or tissue blocks, see our guide to preparing for a cancer pathology review in China.
How much does ivonescimab treatment cost in China?
Here’s when you can find out what each step costs.
The initial enquiry is free. MedBridgeNZ reviews your enquiry and explains how to get started.
Hospital video consultation. We can explain what the quoted fee covers and flag any separate coordination or interpretation charges before you book.
Treatment in China. For the Jiahui and GoBroad routes we coordinate, the hospital needs to assess the case before it can estimate treatment costs. The estimate depends on the proposed medicines and any tests, infusion services, monitoring or hospital care.
If you receive a treatment estimate, check how much care it covers. A figure for the first hospital visit can look very different from one that includes several infusions and repeat scans. Check which items are included and budget separately for travel, accommodation and any costs billed outside the hospital estimate.
What should you confirm before booking travel?
Find out what the hospital expects to do on the first visit. It might be a further assessment, testing or the start of treatment. Confirm whether you’ll need day treatment or a hospital stay and when the team expects to review you again. The hospital works out the timing and expected length of stay for each case.
Ask who will monitor side effects during treatment and how y
our local team can take over follow-up if you return home. Risks include serious immune-related reactions, bleeding, high blood pressure and protein in the urine. Combining ivonescimab with chemotherapy adds risks from the other medicines. See the Chinese prescribing information.
In a case published by Jiahui in March 2026, a US patient travelled to Shanghai after a video consultation. He needed a short stay in intensive care for an immune-related complication. The hospital reported that his condition had stabilised by the time it published the account. If you’re planning care abroad, ask who would look after your family member if a serious side effect occurred. See Jiahui’s published patient account.
What did the HARMONi trials find?
The trial names are similar, but the treatment settings differ. Progression-free survival (PFS) measures time until the cancer worsens or the patient dies. Overall survival (OS) measures how long trial participants lived from random assignment. Both figures describe groups of patients.
Study | What it compared | Main findings |
In China, ivonescimab plus chemotherapy versus placebo plus chemotherapy after progression following EGFR-TKI treatment. | In the final analysis, median OS was 16.8 months with ivonescimab plus chemotherapy and 14.1 months in the comparison group. | |
A multiregional study of ivonescimab plus chemotherapy versus placebo plus chemotherapy after progression following a third-generation EGFR-TKI. | PFS improved. The final OS analysis did not show a statistically significant improvement. The FDA considered the later follow-up analyses exploratory and raised concerns about how well the results applied to US patients. | |
In China, first-line ivonescimab alone versus pembrolizumab alone in selected patients with PD-L1-positive advanced NSCLC. | Median PFS was 11.1 versus 5.8 months. A planned interim analysis reported median OS of 30.8 versus 22.6 months. 2026 IASLC update | |
In China, first-line ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy for advanced squamous NSCLC. | PFS improved. In the planned interim analysis, median OS was 27.9 versus 23.7 months. |
The multiregional HARMONi study included some of the same participants as HARMONi-A. The figures in each row compare groups within that study. Your oncologist can explain which comparison is most relevant to your situation. Summit explains the overlap in its SEC filing.
In HARMONi-2, severe treatment-related side effects (grade 3 or higher) were reported in 29% of participants on ivonescimab and 16% of those on pembrolizumab. The figures cover the two groups receiving a single drug in the published HARMONi-2 analysis.
Frequently asked questions
Can ivonescimab be used without chemotherapy?
Yes, one of China’s three approved uses is as a first treatment on its own. That use applies to selected patients with locally advanced or metastatic NSCLC whose EGFR and ALK results are negative and whose PD-L1 score is at least 1% on an approved test. See the Chinese prescribing information.
What if I have the scan report but can’t access the DICOM images?
Mention this in your enquiry. The written report contains the radiologist’s findings. DICOM files contain the original images. The hospital can tell you whether the report is enough for the first review and when the images will be needed.
How MedBridgeNZ can help
If you’re weighing up care in China, tell us the diagnosis, which records you have and the one question you most want an oncologist to answer. We can explain how to share your records and help you work out what the hospital needs before you book a video consultation.
MedBridgeNZ is a medical concierge and logistics coordinator. We do not provide medical advice, diagnosis or treatment. The hospital’s clinicians assess suitability and make decisions about care.



